COVID-19 Clinical Guidelines–Special Populations

If we can assist your organization in the battle against COVID-19, whether or not you are a current member, please contact us today at clientservices@ecri.org.

Guidance for the care of neuromuscular patients during the COVID-19 pandemic outbreak from the French Rare Health Care for Neuromuscular Diseases Network

Date: 2020 Jun
Developer: French Rare Health Care for Neuromuscular Diseases Network

Guideline Focus
Management of neuromuscular disease during the COVID-19 pandemic

Patient Population
Patients with neuromuscular disease during the COVID-19 pandemic

Major Interventions

  • Management of communication, appointments, and alterations to the availability of physiotherapy
  • Modifications to treatments usually administered during hospitalization
  • Considerations for immunosuppressive, immunomodulating, and cardiac treatments
  • Conduction of clinical trials
  • Considerations for routine treatment and emergency management in the context of COVID-19

Cardio‐oncology care in the era of the coronavirus disease 2019 (COVID‐19) pandemic: an International Cardio‐Oncology Society (ICOS) statement

Date: 2020 Nov
Developer: International Cardio‐Oncology Society (ICOS)

Guideline Focus
Cardiac safety among patients with cancer during and after this COVID-19 pandemic

Patient Population
Patients with cancer and cardiovascular disease

Major Interventions

  • Infection prevention measures, including personal protection equipment (PPE)
  • Role of virtual consultation and considerations for cardiovascular surveillance
  • Prevention and management of cardiac complications, including for specific medication regimens
  • Considerations for radiation therapy
  • Use of angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) during COVID-19
  • Considerations for cancer therapies with risk of arrhythmia, QT prolongation, and thromboembolism

Evidence-based management of COVID-19 in cancer patients: guideline by the Infectious Diseases Working Party of the German Society for Haematology and Medical Oncology (DGHO)

Date: 2020 Nov
Developer: German Society for Haematology and Medical Oncology (DGHO)

Guideline Focus
Prevention, diagnostics, and treatment of SARS-CoV-2 infection and COVID-19, as well as, strategies towards safe antineoplastic care during the COVID-19 pandemic

Patient Population
Adult patients with solid tumours or haematological malignancies with or suspected of COVID-19

Major Interventions

  • Risk factors for severe COVID-19
  • Preventive measures, including distancing, masks, personal protective equipment (PPE), disinfection, and ventilation
  • Organizational aspects of management, including infection prevention and treatment provision
  • Management of cancer care, including indications for therapy delay or discontinuation
  • Diagnostic testing and treatment for infection, including molecular, blood antigen and antibody testing, and thoracic imaging
  • Guidance on treatment options, including antiviral or immunomodulatory treatment, supportive therapy, and anticoagulation

For access to additional guidelines, check out and search the entire ECRI Guidelines Trust® (EGT), a repository of objective, evidence-based clinical practice guidelines.

Return to the ECRI COVID-19 Resource Center